These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 2199034)

  • 1. Are biochemical markers for treatment-resistant schizophrenia state dependent or traits?
    van Kammen DP; Schooler N
    Clin Neuropharmacol; 1990; 13 Suppl 1():S16-28. PubMed ID: 2199034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of adjuvant reserpine treatment on catecholamine metabolism in schizophrenic patients under long-term neuroleptic treatment.
    Bagdy G; Perenyi A; Frecska E; Seregi A; Fekete MI; Tothfalusi L; Magyar K; Bela A; Arato M
    J Neural Transm; 1988; 71(1):73-8. PubMed ID: 3343596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The biochemical basis of relapse and drug response in schizophrenia: review and hypothesis.
    van Kammen DP
    Psychol Med; 1991 Nov; 21(4):881-95. PubMed ID: 1685791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug.
    Skogh E; Sjödin I; Josefsson M; Dahl ML
    J Clin Psychopharmacol; 2011 Feb; 31(1):4-9. PubMed ID: 21192135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin, dopamine and schizophrenia.
    Garver DL; Beinfeld MC; Yao JK
    Psychopharmacol Bull; 1990; 26(3):377-80. PubMed ID: 2274639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma and CSF HVA before and after pharmacological treatment.
    Sharma R; Javaid JI; Janicak P; Faull K; Comaty J; Davis JM
    Psychiatry Res; 1989 Apr; 28(1):97-104. PubMed ID: 2740469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptics reduce spinal fluid cyclic AMP in schizophrenic patient.
    Biederman J; Rimon R; Ebstein R; Zohar J; Belmaker R
    Neuropsychobiology; 1976; 2(5-6):324-7. PubMed ID: 197445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Higher cerebrospinal fluid angiotensin-converting enzyme levels in neuroleptic-treated than in drug-free patients with schizophrenia.
    Wahlbeck K; Ahokas A; Miettinen K; Nikkilä H; Rimón R
    Schizophr Bull; 1998; 24(3):391-7. PubMed ID: 9718631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of schizophrenia. Overview of recent research.
    Marder SR; Wirshing WC; Van Putten T
    Schizophr Res; 1991; 4(2):81-90. PubMed ID: 1674883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.
    Rimón R; Averbuch I; Rozick P; Fijman-Danilovich L; Kara T; Dasberg H; Ebstein RP; Belmaker RH
    Psychopharmacology (Berl); 1981; 73(2):197-9. PubMed ID: 6785816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma catecholamine metabolites as markers for psychosis and antipsychotic response in schizophrenia.
    Kelley ME; Yao JK; van Kammen DP
    Neuropsychopharmacology; 1999 Jun; 20(6):603-11. PubMed ID: 10327429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum.
    Garver DL; Holcomb JA; Christensen JD
    J Clin Psychiatry; 2000 Dec; 61(12):964-72; quiz 973. PubMed ID: 11206608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment-resistant schizophrenia--the role of clozapine.
    Meltzer HY
    Curr Med Res Opin; 1997; 14(1):1-20. PubMed ID: 9524789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclic GMP in the CSF of patients with schizophrenia before and after neuroleptic treatment.
    Ebstein RP; Biederman J; Rimon R; Zohar J; Belmaker RH
    Psychopharmacology (Berl); 1976 Dec; 51(1):71-4. PubMed ID: 13448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The dopamine-serotonin relationship in clozapine response.
    Szymanski S; Lieberman J; Pollack S; Munne R; Safferman A; Kane J; Kronig M; Cooper T
    Psychopharmacology (Berl); 1993; 112(1 Suppl):S85-9. PubMed ID: 7530378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Catecholamine levels in plasma and cerebrospinal fluid of neurosurgical patients with normal and elevated intracranial pressure].
    Rudolph C; Schaffranietz L; Jaeger M; Vetter B; Meixensberger J; Olthoff D
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2004 Oct; 39(10):603-9. PubMed ID: 15486803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of pimozide on CSF norepinephrine in schizophrenia.
    Sternberg DE; van Kammen DP; Lake CR; Ballenger JC; Marder SR; Bunney WE
    Am J Psychiatry; 1981 Aug; 138(8):1045-50. PubMed ID: 7258379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Problems in classification of schizophrenics as neuroleptic responders and nonresponders.
    Csernansky JG; Kaplan J; Hollister LE
    J Nerv Ment Dis; 1985 Jun; 173(6):325-31. PubMed ID: 2860202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of monoamine metabolites and chlorpromazine in cerebrospinal fluid for prediction of therapeutic response in psychotic patients treated with neuroleptic drugs.
    Sedvall G
    Prog Biochem Pharmacol; 1980; 16():133-40. PubMed ID: 6160594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia.
    Meltzer HY; Sommers AA; Luchins DJ
    J Clin Psychopharmacol; 1986 Dec; 6(6):329-38. PubMed ID: 2879856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.